LUNGadenosine: A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells

• Sponsor: Centre Hospitalier Universitaire de Nice (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05648188
• Collaborator: (none)
• Enrollment: 60
• Location: 1
• Anticipated Duration (Months): 21.9
• Patients Per Site Per Month: 2.7

Study Details

Study Description

Brief Summary

Early non-small cell lung cancer (NSCLC), treated by surgery or radiotherapy in the case of inoperability, relapses in almost 50% of cases. Circulating tumour cells (CTCs), which can be detected before surgery, represent a promising prognostic tool, but the markers characterising their aggressiveness remain to be determined. The NSCLC microenvironment, in which purinergic signalling is a key pathway, controls tumour development. Adenosine derived from the action of CD39 and CD73 ectonucleotidases hydrolysing extracellular ATP, induces immunosuppression of NSCLC by activating A2R receptors. The expression and prognostic relevance of A2R, CD39 and CD73 on CTCs is unknown. The objectives are to (i) compare the expression of A2R and CD39 and CD73 on primary tumour cells and CTCs of patients operated on for early NSCLC, (ii) correlate these data with molecular characteristics and clinical response, (iii) determine on lung cancer lines whether irradiation impacts on the expression of A2R, CD39 and CD73. This work could contribute to the identification of new theranostic biomarkers.

Condition or Disease	Intervention/Treatment	Phase
Non Small Cell Lung Cancer	Biological: Sample

Study Design

• Study Type: Observational
• Anticipated Enrollment: 60 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Assessing the Expression of A2R Receptors and CD39 and CD73 Ectonucleotidases on Circulating Tumour Cells of Non-small Cell Lung Carcinoma
• Anticipated Study Start Date: Jan 1, 2023
• Anticipated Primary Completion Date: Oct 30, 2024
• Anticipated Study Completion Date: Oct 30, 2024

Arms and Interventions

Arm	Intervention/Treatment
NSCLC patients Patients with proven stage IA-IIB non-small cell lung cancer (NSCLC).	Biological: Sample; Sample of whole blood and tissue for ex vivo expression of A2R, CD39, CD73 and P2RX7

Outcome Measures

Primary Outcome Measures

1. Ex vivo expression of A2R (adenosine receptor), CD39, CD73 and P2RX7 on NSCLC and CTC [At inclusion]

   Presence versus Absence of expression (immunohistochemistry)

Secondary Outcome Measures

1. In vitro impact of radiation therapy on the A2R, CD39, CD73 expression by cells lineage [At inclusion]

   Upregulation / Downregulation of expression (mRNA by real time PCR)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

1. Inclusion criteria:

• Patient of legal age (>18 years), any gender,

• operated on for stage (IA to IIB) non-small cell lung cancer (NSCLC)

1. Exclusion criteria:

• Patient with any other active cancer.

• Lack of evaluable material.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	CHU de Nice	Nice		France	06001

Sponsors and Collaborators

• Centre Hospitalier Universitaire de Nice

Investigators

• Principal Investigator: Jonathan BENZAQUEN, Dr, Centre Hospitalier Universitaire de Nice

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Centre Hospitalier Universitaire de Nice
• ClinicalTrials.gov Identifier: NCT05648188
• Other Study ID Numbers: 22Pneumo01
• First Posted: Dec 13, 2022
• Last Update Posted: Dec 13, 2022
• Last Verified: Dec 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Lung Neoplasms; Neoplastic Cells, Circulating

Study Results

No Results Posted as of Dec 13, 2022